Premium
Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state
Author(s) -
Cardot J.M.,
Degen P.,
Flesch G.,
Menge P.,
Dieterle W.
Publication year - 1995
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510160708
Subject(s) - oxcarbazepine , saliva , active metabolite , metabolite , chemistry , stimulation , pharmacology , plasma concentration , pharmacokinetics , chromatography , medicine , biochemistry , epilepsy , carbamazepine , psychiatry
A study was performed in ten patients, stabilized with oxcarbazepine monotherapy (450–750 mg bid) for two weeks minimum, to investigate the possibility of using saliva to monitor the oxcarbazepine therapy. Thirteen paired blood and saliva samples were taken over 24h. The saliva samples were obtained after stimulation. The analysis performed on the data suggests a dose dependence for the relationship between plasma and saliva concentrations of the main active metabolite, 10, 11‐dihydro‐10‐hydroxycarbamazepine (MHD), and the importance of the type of stimulation for the saliva's production. Therefore it would be preferable to use plasma concentrations to monitor oxcarbazepine therapy, if necessary.